



AMAZING GOAL



Prof. Rick Stevens with Argonne National Laboratory (ANL) is using deep learning to help move science closer to curing cancer.

Cancer has proven itself as a formidable opponent. But every opponent has a weakness and Rick Stevens is working to identify it, exploit it, and, ultimately, bring the disease to its knees.

How? With supercomputing-powered deep learning.

Prof. Rick Stevens is an associate laboratory director at ANL and a principal investigator on a program that's part of the Cancer Moonshot—a sweeping all-government approach to the problem of cancer.

Called the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C), the program relies on team science, bringing the combined forces of U.S. Department of Energy (DOE) supercomputing labs and the National Cancer Institute (NCI) and its national laboratory to bear on cancer research.

And Rick Stevens is helping lead the charge.

JDACS4C is focused on three critical pilot projects—understanding key protein interactions, predicting drug response, and automating patient information extraction to inform treatment strategies.

Case study

Argonne National Laboratory

Industry

Medical Research

“This model will learn across many types of cancer, many types of drug structures, and many types of data. And it would be something we could keep adding to, so it gets smarter over time.”

– Prof. Rick Stevens, Argonne National Laboratory

Argonne National Laboratory

Argonne is a multidisciplinary science and engineering research center that leads discovery in a wide range of disciplines from high-energy physics and materials science to biology and advanced computer science.

System details

- Intel® Xeon Phi™ processors
- 9.65 PF peak performance
- 20 racks
- 3,624 nodes; 231,935 cores
- Aries interconnect with Dragonfly configuration
- 10 PB Lustre file system

Cray was acquired by Hewlett Packard Enterprise in 2019, and this case study was originally published in 2019. Browse hpe.com/info/hpc for our latest supercomputing technologies and solutions.

All three pilots are linked together by a common thread—data. Specifically, plumbing the already copious amounts of data for new hypotheses, drug targets, and treatments.

“It’s a huge computational problem,” says Rick Stevens. “We have lots of data—millions and millions of experiments and expression data. But the models we need are still an open question.”

Making the kind of rapid progress the DOE-NCI partnership envisions means addressing critical needs in computing, data transfer, and data management in cancer research. In other words, they need the capabilities only afforded by deep learning. So in answer, Rick Stevens conceived of and is leading the development of a scalable deep neural network code called CANDLE—or Cancer Distributed Learning Environment—that will address the machine learning aspects of all three key projects.

“We’re building a deep learning model, which is a neural network that combines all of the information that has already been gleaned about drug response in all types of cancer,” says Rick Stevens. “The idea is that this model will learn across many types of cancer, many types of drug structures, and many types of data. And it would be something we could keep adding to, so it gets smarter over time.”

The analysis CANDLE enables will expose cancer’s vulnerabilities as never before.

In fact, Rick Stevens’ work is hitting cancer from two sides. Along with the CANDLE effort, he’s leading one of the three pilot projects. His group is putting ANL’s HPE Cray supercomputer to work on the task of predicting how specific patients and tumors respond to different types of drugs.

“In the U.S., we have about 200 cancer drugs and we know combinations will outperform single applications,” Rick Stevens says. “But combining pairs and triplets is very time consuming. You could have 5 million experiments and if you want multiple treatment and dosage levels it’s even more exponential.”

But to Rick Stevens, the light at the end of the tunnel just keeps getting brighter: “Every day there’s progress in deep learning. It’s amazing.”

LEARN MORE AT

hpe.com/info/hpc

Make the right purchase decision.
Contact our presales specialists.



Chat



Email



Call



Get updates

**Hewlett Packard
Enterprise**

© Copyright 2020 Hewlett Packard Enterprise Development LP. The information contained herein is subject to change without notice. The only warranties for Hewlett Packard Enterprise products and services are set forth in the express warranty statements accompanying such products and services. Nothing herein should be construed as constituting an additional warranty. Hewlett Packard Enterprise shall not be liable for technical or editorial errors or omissions contained herein.

Intel Xeon Phi is a trademark of Intel Corporation in the U.S. and other countries. All third-party marks are property of their respective owners.

a50002427ENW, August 2020